Holen Sie sich die Stockscreener-App
4.98
1.63%
0.08
Vorhandelsmarkt:
4.89
-0.09
-1.81%
Schlusskurs vom Vortag:
$4.90
Offen:
$4.91
24-Stunden-Volumen:
1.20M
Relative Volume:
0.83
Marktkapitalisierung:
$1.62B
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-37.56
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
+6.18%
1M Leistung:
+27.04%
6M Leistung:
+7.10%
1J Leistung:
-36.15%
1-Tages-Spanne:
$4.90
$5.065
1-Wochen-Bereich:
$4.71
$5.105
52-Wochen-Spanne:
$3.675
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.98 | 1.62B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
287.98 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
63.54 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
61.34 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
104.76 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.87 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment - Insider Monkey
GoodRx launches new subscription service focused on erectile dysfunction treatments - MSN
High Growth Tech Stocks In The US To Watch This June 2025 - simplywall.st
GoodRx (GDRX) Expands Services with New Subscription for ED Trea - GuruFocus
GoodRx (GDRX) Expands Services with New Subscription for ED Treatment | GDRX Stock News - GuruFocus
GoodRx (GDRX) Shares Rise with Launch of Erectile Dysfunction Subscription Service - GuruFocus
GoodRx stock gains on new subscription service (GDRX:NASDAQ) - Seeking Alpha
GoodRx (GDRX) Introduces Subscription Service for ED Treatment | - GuruFocus
GoodRx (GDRX) Introduces Subscription Service for ED Treatment | GDRX Stock News - GuruFocus
GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers - marketscreener.com
GoodRx (GDRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
GoodRx Launches Community Link to Offer Independent Pharmacies C - GuruFocus
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing | GDRX Stock News - GuruFocus
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing - MarketScreener
GoodRx Disrupts Pharmacy Market with New Cost-Plus Pricing Model for Independent Stores - Stock Titan
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing – Company Announcement - Financial Times
Jim Cramer Holds Back on GoodRx (GDRX) - MSN
GoodRx: Stabilizing Revenue Amid Healthy Profit Gains - Seeking Alpha
Goodrx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity - MarketScreener
GoodRx Launches Free Developer Tool That Slashes Testing Time and Infrastructure Costs - Stock Titan
GoodRx Holdings Holds Annual Stockholder Meeting - TipRanks
29,380 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Acquired by Deutsche Bank AG - Defense World
AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - simplywall.st
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Head-To-Head Contrast: GoodRx (NASDAQ:GDRX) & Yext (NYSE:YEXT) - Defense World
BNP Paribas Financial Markets Purchases Shares of 39,285 GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Lazard Asset Management LLC Sells 51,337 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Northern Trust Corp - Defense World
GoodRx’s SWOT analysis: prescription savings firm faces pharmacy headwinds - Investing.com
GoodRx to Launch Direct Contracting for Independent Community Pharmacies - marketscreener.com
GoodRx Disrupts Pharmacy Pricing: New Platform Gives Independent Pharmacies Direct Control Over Margins - Stock Titan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst - AOL.com
KeyBanc maintains GoodRx stock Overweight with $6 target By Investing.com - Investing.com Nigeria
KeyBanc maintains GoodRx stock Overweight with $6 target - Investing.com
KeyBanc on GoodRx Holdings Inc. (GDRX): 'Attractive Valuation as We Await Continued Execution' - StreetInsider
Demystifying GoodRx Holdings: Insights From 5 Analyst Reviews - Benzinga
UBS Adjusts Price Target for GoodRx (GDRX) Amid Neutral Rating | - GuruFocus
GoodRx Holdings (GDRX) Price Target Lowered by UBS | GDRX Stock News - GuruFocus
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - TradingView
UBS Adjusts Price Target for GoodRx (GDRX) Amid Neutral Rating | GDRX Stock News - GuruFocus
UBS Adjusts Price Target on GoodRx Holdings to $5.25 From $6, Maintains Neutral Rating - marketscreener.com
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
The Goldman Sachs Group Cuts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - Defense World
Dimensional Fund Advisors LP Raises Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Wells Fargo & Company MN Sells 81,454 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2025 Earnings Call Transcript - Insider Monkey
GoodRx Holdings (GDRX) Price Target Lowered by Goldman Sachs | G - GuruFocus
Envestnet Asset Management Inc. Takes $84,000 Position in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings Inc (GDRX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.38%
2.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):